CEL-SCI
Corporation (NYSE MKT: CVM), a late-stage oncology company,
today announced that the Company is a Gold Sponsor of the European
Congress on Head and Neck Oncology (ECHNO 2014), which will be held
in Liverpool, England from April 24th through 26th,
2014. CEL-SCI will sponsor a symposium regarding its investigational
immunotherapy candidate Multikine®* (Leukocyte Interleukin, Injection)
and its ongoing Phase III head and neck cancer trial with Multikine.
Company representatives will be available at conference booth #10.
In Europe alone CEL-SCI currently has 32 clinical sites participating in
the Phase III clinical trial and plans to increase this number to 50 to
60 sites. The trial, which is the largest Phase III study for head and
neck cancer in the world, is designed to include a total of about 100
sites in Europe, Asia, the Middle East, and North America.
ECHNO is the European
Head and Neck Cancer Society’s meeting which is held every two
years. At ECHNO 2014 an emphasis has been placed on addressing the need
for a multidisciplinary approach to facilitate cooperation between the
various clinical and research specialties involved in the management of
head and neck cancer. ECHNO 2014 will provide attendees with the latest
research and techniques in the ongoing effort to improve the lives of
patients everywhere.
On Thursday April 24th from 13:30 to 14:30 local time,
CEL-SCI executives, along with one of the principal investigators of its
Phase III trial, will participate in a CEL-SCI hosted symposium and
discussion on its Multikine Phase III clinical trial for head and neck
cancer. The program will feature an overview of the Phase III head and
neck cancer trial by Dr. Talor, Chief Scientific Officer of CEL-SCI, and
a discussion of the clinical experience with Multikine by Professor
Raphael Feinmesser, MD, Chairman of the Department of Otolaryngology
Head & Neck Surgery at the Rabin Medical Center, Israel, and a Principal
Investigator in the Multikine Phase III study.
“Our ECHNO 2014 presentation to many of the world’s leading experts in
head and neck cancer comes at a pivotal time for our Phase III trial.
Under the guidance of the new Clinical Research Organizations (CROs), we
have accelerated the pace of the trial through a rapid increase in the
number of participating clinical sites and a very substantial increase
in patient enrollment. We expect that many of the investigators
participating in our trial will be attending the conference and we look
forward to a very meaningful exchange amongst the clinicians regarding
their experience with Multikine. As we continue to expand our trial in
Europe and beyond, ECHNO will be a great opportunity to interact with
additional physicians and clinical centers interested in taking part in
our study,” stated CEL-SCI Chief Executive Officer Geert Kersten.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving
the treatment of cancer and other diseases by utilizing the immune
system, the body's natural defense system. Its lead investigational
therapy is Multikine (Leukocyte Interleukin, Injection), currently being
studied in a pivotal global Phase III clinical trial. CEL-SCI is also
investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment
for H1N1 hospitalized patients and as a vaccine (CEL-2000) for
Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS
technology platform. The investigational immunotherapy LEAPS-H1N1-DC
treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu
(H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned
about the possible emergence of a new more virulent hybrid virus through
the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company
has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
* Multikine is the trademark that CEL-SCI has registered for this
investigational therapy, and this proprietary name is subject to FDA
review in connection with its future anticipated regulatory submission
for approval. Multikine has not been licensed or approved for
sale, barter or exchange by the FDA or any other regulatory
agency. Similarly, its safety or efficacy has not been established for
any use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational therapy
Multikine (Leukocyte Interleukin, Injection). Further research is
required, and early-phase clinical trial results must be confirmed in
the well-controlled, Phase III clinical trial of this investigational
therapy that is currently in progress.
Safe Harbor Statement
When used in this release, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Forward-looking statements include,
without limitation, the company’s ability to complete the proposed
public offering of its common stock and warrants described above. Such
statements are subject to risks and uncertainties which could cause
actual results to differ materially from those projected. The Company
undertakes no obligation to publicly release the result of any revision
to these forward-looking statements which may be made to reflect the
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
Copyright Business Wire 2014